Selected articles
Articles for label Liberko Marián are displayed.. Show all articles
Pancreatic cancer – current treatment options
03/2021 MUDr. Marián Liberko; doc. MUDr. Renata Soumarová, Ph.D., MBA
Pancreatic cancer represents disease with the worst long-term survival across all malignancies. In clinical practice, due to asymptomatic or non-specific signs and symptoms we diagnose patients mainly with locally advanced and metastatic disease, where median survival is approximately one year. Nevertheless, even in early stages after curative surgery we observe early local recurrence, or distant metastases and long-term survival is an exception even in early stages of disease. Nevertheless, in the last few years there is an improvement in median overall survival also in patients with pancreatic cancer. It is due to advancements in diagnostics, surgery, but mainly due to improvements in cancer treatment (chemotherapy - adjuvant, neoadjuvant, perioperative, induction and palliative, and also radiotherapy). There were published results of many studies across all stages (resectable, borderline resectable, locally advanced, metastatic) which showed improved survival. The aim of this article is to provide overview of current treatment options for pancreatic ductal adenocarcinoma.
ENTIRE ARTICLE
Pancreatic cancer represents disease with the worst long-term survival across all malignancies. In clinical practice, due to asymptomatic or non-specific signs and symptoms we diagnose patients mainly with locally advanced and metastatic disease, where median survival is approximately one year. Nevertheless, even in early stages after curative surgery we observe early local recurrence, or distant metastases and long-term survival is an exception even in early stages of disease. Nevertheless, in the last few years there is an improvement in median overall survival also in patients with pancreatic cancer. It is due to advancements in diagnostics, surgery, but mainly due to improvements in cancer treatment (chemotherapy - adjuvant, neoadjuvant, perioperative, induction and palliative, and also radiotherapy). There were published results of many studies across all stages (resectable, borderline resectable, locally advanced, metastatic) which showed improved survival. The aim of this article is to provide overview of current treatment options for pancreatic ductal adenocarcinoma.
Significant response to neoadjuvant treatment in locally advanced pancreatic cancer – case report
05/2020 MUDr. Marián Liberko; doc. MUDr. Renata Soumarová, Ph.D., MBA
This case report describes a patient with locally advanced pancreatic cancer. By combination of chemotherapy and chemoradiotherapy, conversion of unresectable disease (locally advanced pancreatic cancer) in to resectable disease with significant pathological response was achieved.
ENTIRE ARTICLE
This case report describes a patient with locally advanced pancreatic cancer. By combination of chemotherapy and chemoradiotherapy, conversion of unresectable disease (locally advanced pancreatic cancer) in to resectable disease with significant pathological response was achieved.
Inclusion of chemoradiotherapy to primary tumor in patient with synchronous liver metastases – case report
01/2020 Special Edition - MUDr. Marián Liberko; doc. MUDr. Renata Soumarová, Ph.D.
Case report describes a case of patient with stenosing rectal cancer and multiple liver metastases. Systemic chemobiotherapy (mFOLFOX6 + Vectibix) led to significant response of liver metastases enabling curative surgical resection of liver metastases - liver first approach. Subsequent chemoradiotherapy of primary rectal cancer led to significant regression based on imaging methods and patient was indicated to curative surgery of rectal cancer. Combination of modalities of oncological treatment may represent in selected group of patients with metastatic colorectal cancer potentially curative approach with chance of long-term survival.
ENTIRE ARTICLE
Case report describes a case of patient with stenosing rectal cancer and multiple liver metastases. Systemic chemobiotherapy (mFOLFOX6 + Vectibix) led to significant response of liver metastases enabling curative surgical resection of liver metastases - liver first approach. Subsequent chemoradiotherapy of primary rectal cancer led to significant regression based on imaging methods and patient was indicated to curative surgery of rectal cancer. Combination of modalities of oncological treatment may represent in selected group of patients with metastatic colorectal cancer potentially curative approach with chance of long-term survival.
The importance of radiotherapy of primary tumor in synchronous metastatic disease
01/2020 Special Edition - Doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Tomáš Blažek; MUDr. Marián Liberko
Radiotherapy has an important role in treatment of malignant tumors. It is usually used in treatment of localized disease in combination with surgery or as a curative treatment with or without chemotherapy. In metastatic setting, radiotherapy has palliative intent with the aim to relief from suffering. Nevertheless, with improvements in radiotherapy techniques there are also new indications for radiotherapy. Curative radiotherapy doses and techniques are used in metastatic setting with the aim to improve not only local control but also overall survival. Preclinical and experimental studies prove systemic treatment effect of radiotherapy, which leads to immune reactions also outside of irradiated target volume. Combination of radiotherapy with immunotherapy represents new treatment option. The aim of this review is to provide summary of studies, which studies added effect of radiotherapy of primary tumor in synchronous metastatic disease.
ENTIRE ARTICLE
Radiotherapy has an important role in treatment of malignant tumors. It is usually used in treatment of localized disease in combination with surgery or as a curative treatment with or without chemotherapy. In metastatic setting, radiotherapy has palliative intent with the aim to relief from suffering. Nevertheless, with improvements in radiotherapy techniques there are also new indications for radiotherapy. Curative radiotherapy doses and techniques are used in metastatic setting with the aim to improve not only local control but also overall survival. Preclinical and experimental studies prove systemic treatment effect of radiotherapy, which leads to immune reactions also outside of irradiated target volume. Combination of radiotherapy with immunotherapy represents new treatment option. The aim of this review is to provide summary of studies, which studies added effect of radiotherapy of primary tumor in synchronous metastatic disease.
Complete and long‑term response of HER2 positive locally highly advanced metastatic breast cancer – case report
04/2019 MUDr. Lenka Rušinová; doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Marián Liberko
Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.
ENTIRE ARTICLE
Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.